All In Biotech

NDA 017584 · Fresenius Kabi USA

Lidocaine Hydrochloride Preservative Free

Lidocaine Hydrochloride · Injection

Last checked: Nov 20, 2026Latest source record: Aug 17, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1976

Mar 26, 1976

Approved uses

1

Original approval plus efficacy supplements

Registered trials

2,569

373 Phase 3, 196 recruiting

FAERS reports

56,266

40,694 serious, 5,613 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Feb 20, 2025.

INDICATIONS AND USAGE Lidocaine Hydrochloride Injection, USP administered intravenously is specifically indicated in the acute management of 1) ventricular arrhythmias occurring during cardiac manipulation such as cardiac surgery, and 2) life-threatening arrhythmias, particularly those which are ventricular in origin, such as those which occur during acute myocardial infarction.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Mar 26, 1976 Original approval · Type 5 - New Formulation or New Manufacturer
2 products under this application
  • LIDOCAINE HYDROCHLORIDE PRESERVATIVE FREE · LIDOCAINE HYDROCHLORIDE 4% · INJECTABLE, INJECTION · Prescription · TE AP
  • LIDOCAINE HYDROCHLORIDE PRESERVATIVE FREE · LIDOCAINE HYDROCHLORIDE 2% · INJECTABLE, INJECTION · Prescription · TE AP

Clinical trials

Interventional ClinicalTrials.gov studies with "Lidocaine" as an intervention, any sponsor and status, largest first.

All 2,569 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug ineffective4,108
  • nausea3,576
  • pain3,541
  • fatigue3,469
  • headache3,296
  • off label use3,070
  • dyspnoea2,650
  • diarrhoea2,417
  • pneumonia2,228
  • vomiting2,161
  • dizziness2,037
  • sinusitis1,990

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
2004316
2005275
2006327
2007323
2008402
2009497
2010581
20111,152
20121,299
2013847
20141,187
20152,033
20163,318
20172,668
20183,430
20194,276
20205,560
20214,031
20224,061
20234,787
20245,375
20255,470
20264,047

Recalls

1 FDA enforcement reports for this application.

  • Jul 16, 2026 · Class II · Ongoing

    Presence of Particulate Matter: Hair was found in products

Shortages

FDA's drug shortage list.

  • Current · updated Nov 18, 2026

    Lidocaine Hydrochloride Preservative Free, Injection, 20 mg/1 mL (NDC 63323-208-05). Demand increase for the drug

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 6,282 on PubMed

Sponsor: Fresenius Kabi USA

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.